title: Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels.
abstract: Reduction in transfection time and the ability to perform gene transfer in conjunction with endovascular stent implantation constitute two important challenges for percutaneous adenovirus-mediated gene transfer to vessel walls. Studies have suggested that the use of biocompatible polyol poloxamer 407 could be useful. We first evaluated the use of poloxamer 407 for percutaneous gene transfer in nonstented rabbit iliac arteries. A 200-microl mixture of Ad-RSVbetagal or Ad-CMVLuc in either phosphate-buffered saline (PBS) or 20% poloxamer was delivered. After 3 days, gene transfection was evaluated by X-Gal staining or measurement of luciferase activity. Poloxamer use resulted in a 3- to 15-fold increase in the percentage of transfected cells (X-Gal, p = 0.001) and a 16-fold increase in protein product (luciferase activity, p = 0.03), and allowed a decrease in transfection time from 30 to 5 min with minimal reduction in transfection efficiency. We then evaluated the feasibility of percutaneous gene transfer, using Ad-RSVbetagal diluted in pure PBS or 20% poloxamer, in conjunction with stent implantation. Gene delivery was performed either immediately before (pre-) or after (post-) stent implantation. When adenoviruses were diluted in PBS, gene transfer had a low efficiency (prestent, 0.3%; poststent, 0.2%; NS). With poloxamer, the efficacy was much higher (p = 0.0001) and similar "pre" (2.2%) or "post" (1.7%) stent delivery (NS).
  
  
  CONCLUSIONS
  (1) The use of poloxamer, rather than PBS, as a vehicle increases the efficacy of percutaneous adenovirus-mediated gene transfer and reduces transfection time; (2) gene transfer performed during stent implantation with poloxamer is feasible and achieves a significant level of gene expression. Thus percutaneous gene delivery is applicable to conventional stents and could present an attractive method by which to achieve local biological effects in a stent environment.
authors.affiliation: Department of Medicine (Cardiology), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA.
authors.forename: E
authors.initials: E
authors.lastname: Van Belle
authors.forename: L
authors.initials: L
authors.lastname: Maillard
authors.forename: A
authors.initials: A
authors.lastname: Rivard
authors.forename: J E
authors.initials: JE
authors.lastname: Fabre
authors.forename: T
authors.initials: T
authors.lastname: Couffinhal
authors.forename: M
authors.initials: M
authors.lastname: Kearney
authors.forename: D
authors.initials: D
authors.lastname: Branellec
authors.forename: L J
authors.initials: LJ
authors.lastname: Feldman
authors.forename: K
authors.initials: K
authors.lastname: Walsh
authors.forename: J M
authors.initials: JM
authors.lastname: Isner
mesh_terms: D000260:Adenoviruses, Human; D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001672:Biocompatible Materials; D005260:Female; D018014:Gene Transfer Techniques; D017930:Genes, Reporter; D005822:Genetic Vectors; D006801:Humans; D007083:Iliac Artery / Q000378:metabolism*; D007763:Lac Operon; D008163:Luminescent Measurements; D011060:Poloxalene; D011817:Rabbits; D015607:Stents; D013997:Time Factors; D014162:Transfection
chemical_list: D001672:Biocompatible Materials; D011060:Poloxalene